[1]
Bolaños-Díaz, R. et al. 2017. Cost-effectiveness of two antiviral therapies for chronic hepatitis B in Peru: entecavir and tenofovir. Revista Peruana de Medicina Experimental y Salud Pública. 34, 3 (Sep. 2017), 377–85. DOI:https://doi.org/10.17843/rpmesp.2017.343.2496.